CCR4 and cancer: The terminally differentiated and most suppressive effector Treg cells predominantly express CCR4 in both cancer tissues and peripheral blood and anti-CCR4 mAb treatment selectively depletes effector Treg cells and induces anti-tumor immunity (35).